Taysha Gene Therapies, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
RA Capital Management, along with its affiliates, has reported a beneficial ownership of 9.9% in Taysha Gene Therapies, Inc., primarily through a significant holding of common stock and pre-funded warrants.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have filed an amended Schedule 13G, reporting a combined beneficial ownership of 5.1% in Taysha Gene Therapies, Inc.
NASDAQ
Vestal Point Capital, LP and Ryan Wilder have filed a Schedule 13G reporting a 6.3% beneficial ownership stake in Taysha Gene Therapies, Inc.
NASDAQ
RTW Investments, LP and Roderick Wong have reported a significant beneficial ownership stake of 7.0% in Taysha Gene Therapies, Inc., holding over 20.6 million shares.
NASDAQ
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 8.3% in Taysha Gene Therapies, Inc., including warrants.
NASDAQ
FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 4.9% in Taysha Gene Therapies Inc., marking a reduction below the 5% threshold.
NASDAQ
SCHEDULE 13G/A: BlackRock Boosts Taysha Gene Therapies Stake to 6.5%
BlackRock, Inc. has reported a 6.5% beneficial ownership stake in Taysha Gene Therapies Inc. common stock as of December 31, 2025.
NASDAQ
Octagon Capital Advisors LP and its affiliates have reported a 3.3% beneficial ownership stake in Taysha Gene Therapies, Inc., totaling 9,067,500 common shares.
NASDAQ
SCHEDULE 13G/A: RA Capital Boosts Taysha Gene Therapies Stake to 9.9%
RA Capital Management and its affiliates have disclosed a 9.9% beneficial ownership stake in Taysha Gene Therapies, holding 27.66 million shares.
NASDAQ
RA Capital Management and its affiliates have reported a 9.9% beneficial ownership stake in Taysha Gene Therapies, Inc., holding 25.3 million shares as of June 30, 2025.
NASDAQ
RTW Investments and Roderick Wong report a 9.9% beneficial ownership stake in Taysha Gene Therapies, Inc., holding over 25 million shares.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have reported beneficial ownership of 6.7% of Taysha Gene Therapies, Inc.'s common stock as of June 30, 2025.
NASDAQ
FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.2% beneficial ownership stake in Taysha Gene Therapies Inc. as of June 30, 2025.
NASDAQ
BlackRock, Inc. has filed an amended Schedule 13G, revealing a 5.2% beneficial ownership stake in Taysha Gene Therapies Inc.
NASDAQ
The Goldman Sachs Group, Inc. and its affiliate Goldman Sachs & Co. LLC have reported a passive beneficial ownership of 5.1% in Taysha Gene Therapies, Inc., totaling 12,748,968 shares of common stock.
NASDAQ
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a beneficial ownership of 9.99% in Taysha Gene Therapies, Inc., totaling 20,673,307 shares of common stock.
NASDAQ
SCHEDULE 13G/A: RTW Investments and Dr. Roderick Wong Disclose 5.9% Passive Stake in Taysha Gene Therapies
RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have filed an amended Schedule 13G, reporting a 5.9% passive beneficial ownership stake in Taysha Gene Therapies, Inc. as of December 31, 2024.
NASDAQ
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 8.0% in Taysha Gene Therapies Inc. as of December 31, 2024.
NASDAQ
SCHEDULE 13G: Octagon Capital Advisors and Affiliates Disclose 5.1% Passive Stake in Taysha Gene Therapies
Octagon Capital Advisors LP, Octagon Investments Master Fund LP, and Ting Jia have jointly reported a 5.1% beneficial ownership stake in Taysha Gene Therapies, Inc., held for investment purposes.
NASDAQ
Morgan Stanley and its subsidiary, Morgan Stanley Capital Services LLC, have disclosed beneficial ownership of 8.6% and 7.0% respectively, of Taysha Gene Therapies, Inc.'s common stock as of December 31, 2024.